These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 19414862)

  • 1. In utero transplantation of adult bone marrow decreases perinatal lethality and rescues the bone phenotype in the knockin murine model for classical, dominant osteogenesis imperfecta.
    Panaroni C; Gioia R; Lupi A; Besio R; Goldstein SA; Kreider J; Leikin S; Vera JC; Mertz EL; Perilli E; Baruffaldi F; Villa I; Farina A; Casasco M; Cetta G; Rossi A; Frattini A; Marini JC; Vezzoni P; Forlino A
    Blood; 2009 Jul; 114(2):459-68. PubMed ID: 19414862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered cytoskeletal organization characterized lethal but not surviving Brtl+/- mice: insight on phenotypic variability in osteogenesis imperfecta.
    Bianchi L; Gagliardi A; Maruelli S; Besio R; Landi C; Gioia R; Kozloff KM; Khoury BM; Coucke PJ; Symoens S; Marini JC; Rossi A; Bini L; Forlino A
    Hum Mol Genet; 2015 Nov; 24(21):6118-33. PubMed ID: 26264579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone Marrow Transplantation for Treatment of the Col1a2
    Lee LR; Peacock L; Ginn SL; Cantrill LC; Cheng TL; Little DG; Munns CF; Schindeler A
    Calcif Tissue Int; 2019 Apr; 104(4):426-436. PubMed ID: 30535573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brittle IV mouse model for osteogenesis imperfecta IV demonstrates postpubertal adaptations to improve whole bone strength.
    Kozloff KM; Carden A; Bergwitz C; Forlino A; Uveges TE; Morris MD; Marini JC; Goldstein SA
    J Bone Miner Res; 2004 Apr; 19(4):614-22. PubMed ID: 15005849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of the Cre/lox recombination system to develop a non-lethal knock-in murine model for osteogenesis imperfecta with an alpha1(I) G349C substitution. Variability in phenotype in BrtlIV mice.
    Forlino A; Porter FD; Lee EJ; Westphal H; Marini JC
    J Biol Chem; 1999 Dec; 274(53):37923-31. PubMed ID: 10608859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engraftment of skeletal progenitor cells by bone-directed transplantation improves osteogenesis imperfecta murine bone phenotype.
    Sinder BP; Novak S; Wee NKY; Basile M; Maye P; Matthews BG; Kalajzic I
    Stem Cells; 2020 Apr; 38(4):530-541. PubMed ID: 31859429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amelioration of a mouse model of osteogenesis imperfecta with hematopoietic stem cell transplantation: microcomputed tomography studies.
    Mehrotra M; Rosol M; Ogawa M; Larue AC
    Exp Hematol; 2010 Jul; 38(7):593-602. PubMed ID: 20417683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution of single-cell expanded marrow derived progenitors in a developing mouse model of osteogenesis imperfecta following systemic transplantation.
    Li F; Wang X; Niyibizi C
    Stem Cells; 2007 Dec; 25(12):3183-93. PubMed ID: 17823236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential response to intracellular stress in the skin from osteogenesis imperfecta Brtl mice with lethal and non lethal phenotype: a proteomic approach.
    Bianchi L; Gagliardi A; Gioia R; Besio R; Tani C; Landi C; Cipriano M; Gimigliano A; Rossi A; Marini JC; Forlino A; Bini L
    J Proteomics; 2012 Aug; 75(15):4717-33. PubMed ID: 22846432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy.
    Gioia R; Panaroni C; Besio R; Palladini G; Merlini G; Giansanti V; Scovassi IA; Villani S; Villa I; Villa A; Vezzoni P; Tenni R; Rossi A; Marini JC; Forlino A
    Stem Cells; 2012 Jul; 30(7):1465-76. PubMed ID: 22511244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased susceptibility to microdamage in Brtl/+ mouse model for osteogenesis imperfecta.
    Davis MS; Kovacic BL; Marini JC; Shih AJ; Kozloff KM
    Bone; 2012 Mar; 50(3):784-91. PubMed ID: 22207275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular mechanism of decreased bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors.
    Uveges TE; Collin-Osdoby P; Cabral WA; Ledgard F; Goldberg L; Bergwitz C; Forlino A; Osdoby P; Gronowicz GA; Marini JC
    J Bone Miner Res; 2008 Dec; 23(12):1983-94. PubMed ID: 18684089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoscale morphology of Type I collagen is altered in the Brtl mouse model of Osteogenesis Imperfecta.
    Wallace JM; Orr BG; Marini JC; Holl MM
    J Struct Biol; 2011 Jan; 173(1):146-52. PubMed ID: 20696252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta.
    Jacobsen CM; Barber LA; Ayturk UM; Roberts HJ; Deal LE; Schwartz MA; Weis M; Eyre D; Zurakowski D; Robling AG; Warman ML
    J Bone Miner Res; 2014 Oct; 29(10):2297-306. PubMed ID: 24677211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment.
    Sinder BP; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
    Bone; 2015 Feb; 71():115-23. PubMed ID: 25445450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transplantation of human fetal blood stem cells in the osteogenesis imperfecta mouse leads to improvement in multiscale tissue properties.
    Vanleene M; Saldanha Z; Cloyd KL; Jell G; Bou-Gharios G; Bassett JH; Williams GR; Fisk NM; Oyen ML; Stevens MM; Guillot PV; Shefelbine SJ
    Blood; 2011 Jan; 117(3):1053-60. PubMed ID: 21088133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transfer of proalpha2(I) cDNA into cells of a murine model of human Osteogenesis Imperfecta restores synthesis of type I collagen comprised of alpha1(I) and alpha2(I) heterotrimers in vitro and in vivo.
    Niyibizi C; Smith P; Mi Z; Phillips CL; Robbins P
    J Cell Biochem; 2001 Jun 26-Jul 25; 83(1):84-91. PubMed ID: 11500956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlations Between Bone Mechanical Properties and Bone Composition Parameters in Mouse Models of Dominant and Recessive Osteogenesis Imperfecta and the Response to Anti-TGF-β Treatment.
    Bi X; Grafe I; Ding H; Flores R; Munivez E; Jiang MM; Dawson B; Lee B; Ambrose CG
    J Bone Miner Res; 2017 Feb; 32(2):347-359. PubMed ID: 27649409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure, stability and interactions of type I collagen with GLY349-CYS substitution in alpha 1(I) chain in a murine Osteogenesis Imperfecta model.
    Kuznetsova NV; Forlino A; Cabral WA; Marini JC; Leikin S
    Matrix Biol; 2004 May; 23(2):101-12. PubMed ID: 15246109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteogenesis imperfecta: prospects for molecular therapeutics.
    Forlino A; Marini JC
    Mol Genet Metab; 2000; 71(1-2):225-32. PubMed ID: 11001814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.